What are the consensus estimates for XILIO THERAPEUTICS INC (XLO) next earnings?
The consensus EPS estimate for the next earnings of XILIO THERAPEUTICS INC (XLO) is -0.12 USD and the consensus revenue estimate is 8.04M USD.
XILIO THERAPEUTICS INC (XLO) Forecast, Price Target & Analyst Ratings
NASDAQ:XLO • US98422T1007
Current stock price
0.5101 USD
0 (-0.23%)
At close:
0.521 USD
+0.01 (+2.14%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for XILIO THERAPEUTICS INC (XLO).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.12
- Revenue Estimate
- 8.04M
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.51 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.00%
XLO was analyzed by 5 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about XLO.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed XLO. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-08-06 | Leerink Partners | Initiate | Outperform |
| 2024-11-08 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-05-30 | Chardan Capital | Reiterate | Buy -> Buy |
| 2023-05-11 | Chardan Capital | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Maintains | Overweight |
| 2022-12-21 | Chardan Capital | Initiate | Buy |
| 2022-11-10 | Raymond James | Maintains | Outperform |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-01-10 | HC Wainwright & Co. | Initiate | Buy |
| 2021-11-16 | Cowen & Co. | Initiate | Outperform |
| 2021-11-16 | Raymond James | Initiate | Outperform |
| 2021-11-16 | Morgan Stanley | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.12
- Revenue Estimate
- 8.04M
- Revenue Q2Q
- 366.36%
- EPS Q2Q
- 39.40%
- Number of Analysts
- 2
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-15.58%
EPS (1 Month)
0.00%
EPS (3 Months)
-24.35%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 15.58% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.344M | 46.107M 626.78% | 82.568M 79.08% | 13.17M -84.05% | 3.803M -71.12% | 4.414M 16.07% | 2.565M -41.89% | 1.515M -40.94% | 55.146M 3,540.00% | 14.948M -72.89% | |||
| EBITDA YoY % growth | -87.3M -18.71% | -77.233M 11.53% | -58.001M 24.90% | -3.262M 94.38% | -57.57M -1,664.71% | -42.864M 25.54% | -38.168M 10.96% | -14.726M 61.42% | 115.85M 886.71% | N/A | N/A | N/A | |
| EBIT YoY % growth | -89.15M -18.80% | -79.133M 11.24% | -59.645M 24.63% | -45.046M 24.48% | -28.28M 37.22% | -79.891M -182.50% | -237.35M -197.09% | -296.94M -25.11% | -336.33M -13.27% | N/A | N/A | N/A | |
| Operating Margin | N/A | N/A | -940.18% | -97.70% | -34.25% | -606.61% | -6,241.13% | -6,727.23% | -13,112.28% | N/A | N/A | N/A | |
| EPS YoY % growth | -3.22 48.63% | -2.78 13.66% | -1.24 55.40% | -0.44 64.16% | -0.18 59.09% | -0.48 -166.67% | -0.48 | 0.37 176.04% | 1.10 198.63% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 39.40% | -0.14 21.44% | -0.14 11.62% | -0.15 -2,425.00% | 0.25 308.33% |
| Revenue Q2Q % growth | 8.04M 366.36% | 6.969M 137.85% | 6.06M -25.04% | 5.252M -72.45% | 64.236M 698.96% |
| EBITDA Q2Q % growth | -202K 98.31% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -18.584M -36.36% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.18%
EPS Next 5 Year
18.10%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
19.19%
Revenue Next 5 Year
-10.71%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
9.46%
EBIT Next 5 Year
12.01%
XILIO THERAPEUTICS INC / XLO Forecast FAQ
Can you provide the consensus rating for XILIO THERAPEUTICS INC stock?
The consensus rating for XILIO THERAPEUTICS INC (XLO) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.